Cited by 30Psychedelics and Drug StudiesTreatment of Major DepressionTranscranial Magnetic Stimulation Studies

Spectral signatures of psilocybin, lysergic acid diethylamide (LSD) and ketamine in healthy volunteers and persons with major depressive disorder and treatment-resistant depression: A systematic review

Le, Gia Han, Wong, Sabrina, Badulescu, Sebastian, Au, Hezekiah, Di Vincenzo, Joshua D., Gill, Hartej, Phan, Lee, Rhee, Taeho Greg +6 more·2024·Journal of Affective Disorders

Abstract

Background Electrophysiologic measures provide an opportunity to inform mechanistic models and possibly biomarker prediction of response. Serotonergic psychedelics (SPs) (i.e., psilocybin, lysergic acid diethylamide (LSD)) and ketamine represent new investigational and established treatments in mood disorders respectively. There is a need to better characterize the mechanism of action of these agents.Methods We conducted a systematic review investigating the spectral signatures of psilocybin, LSD, and ketamine in persons with major depressive disorder (MDD), treatment-resistant depression (TRD), and healthy controls.Results Ketamine and SPs are associated with increased theta power in persons with depression. Ketamine and SPs are also associated with decreased spectral power in the alpha, beta and delta bands in healthy controls and persons with depression. When administered with SPs, theta power was increased in persons with MDD when administered with SPs. Ketamine is associated with increased gamma band power in both healthy controls and persons with MDD.Limitations The studies included in our review were heterogeneous in their patient population, exposure, dosing of treatment and devices used to evaluate EEG and MEG signatures. Our results were extracted entirely from persons who were either healthy volunteers or persons with MDD or TRD.Conclusions Extant literature evaluating EEG and MEG spectral signatures indicate that ketamine and SPs have reproducible effects in keeping with disease models of network connectivity. Future research vistas should evaluate whether observed spectral signatures can guide further discovery of therapeutics within the psychedelic and dissociative classes of agents, and its prediction capability in persons treated for depression.

Integrity signals

Registry

Crossref · 10.1016/j.jad.2024.03.165

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Cites

Flagged first, then by citations

1 of the 34 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Le, G. H., Wong, S., Badulescu, S., Au, H., Di Vincenzo, J. D., Gill, H., Phan, L., Rhee, T. G., Ho, R., Teopiz, K. M., Kwan, A. T. H., Rosenblat, J. D., Mansur, R. B., & McIntyre, R. S.
Affiliations
  • University Health Network (CA)
  • Brain and Cognition Discovery Foundation (CA)
  • Yale University (US)
  • National University of Singapore (SG)
  • University of Ottawa (CA)
Corresponding author
McIntyre, Roger S.
Venue
Journal of Affective Disorders
Publisher
Elsevier BV
Published
2024-06
Volume
355
Pages
342-354
ISSN
0165-0327 (ISSN-L)
OpenAlex
W4393364883
Cited by
30
References
34
Citations by year
2026: 10 · 2025: 11 · 2024: 9
FWCI
2.67
Type
journal article
Language
en
Open access
closed
Locations
  • Journal of Affective Disorders (publishedVersion)
  • PubMed (publishedVersion)
  • Rare & Special e-Zone (The Hong Kong University of Science and Technology) (submittedVersion)
Funders
  • Canadian Institutes of Health Research
  • National Institute on Aging (R21AG078972, R21AG070666)
  • National Institute of Mental Health (R01MH131528)
  • National Institute on Drug Abuse (R21DA057540)
Topics
  • Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
  • Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
  • Life Sciences › Neuroscience › Neurology › Transcranial Magnetic Stimulation Studies
Keywords
psilocybin, lysergic acid diethylamide, ketamine, serotonergic psychedelics, major depressive disorder, treatment-resistant depression, theta power, gamma power, brain network connectivity, treatment response biomarkers
MeSH terms
Depression, Depressive Disorder, Major, Major Depressive Disorder, Electroencephalography, Hallucinogens, Humans, Ketamine, Lysergic Acid Diethylamide, Psilocybin, Depressive Disorder, Treatment-Resistant, Healthy Volunteers

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review